{"id":49637,"date":"2022-10-14T13:02:32","date_gmt":"2022-10-14T11:02:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/matchpoint-therapeutics-launches-with-100-million-to-deliver-on-the-promise-of-precision-covalent-medicines-for-immune-diseases\/"},"modified":"2022-10-14T13:02:32","modified_gmt":"2022-10-14T11:02:32","slug":"matchpoint-therapeutics-launches-with-100-million-to-deliver-on-the-promise-of-precision-covalent-medicines-for-immune-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/matchpoint-therapeutics-launches-with-100-million-to-deliver-on-the-promise-of-precision-covalent-medicines-for-immune-diseases\/","title":{"rendered":"Matchpoint Therapeutics Launches with $100 Million to Deliver on the Promise of Precision Covalent Medicines for Immune Diseases"},"content":{"rendered":"
\n

\n-Founded by leading experts in covalent chemistry, proteomics, and computational sciences from Stanford University and Harvard Medical School<\/i>\n<\/p>\n

<\/a><\/p>\n

\n-Series A financing led by Sanofi Ventures with participation from Atlas Venture, Access Biotechnology, Vertex Ventures HC, Digitalis Ventures, Alexandria Venture Investments, and others<\/i>\n<\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched today with $100 million in financing. Matchpoint\u2019s funding includes a recently closed $70 million Series A financing led by Sanofi Ventures and joined by Vertex Ventures HC, Digitalis Ventures, Alexandria Venture Investments, other new investors, and all existing investors. The Series A follows a $30 million seed financing round co-led by Atlas Venture and Access Biotechnology in November 2021. The financing will be used to support further advancement of the company\u2019s proprietary platform and its discovery pipeline of novel covalent molecules, initially focused on immunology.\n<\/p>\n

\n\u201cWe created Matchpoint to harness the powerful properties of covalency and enable the targeting of disease-causing proteins otherwise unamenable to small molecule intervention,\u201d said Andre Turenne, President and Chief Executive Officer of Matchpoint. \u201cWe believe the immunology space is greatly underserved by current small molecule therapies and are excited by the potential of our proprietary platform to deliver highly specific covalent medicines for several of its most important and difficult targets.\u201d\n<\/p>\n

\nThe durable target engagement achieved with covalent chemistry imparts improved potency, greater selectivity, and lower systemic exposure than otherwise possible. Matchpoint is pursuing genetically or clinically validated targets for which covalent chemistry is the only or best modality for therapeutic intervention.\n<\/p>\n

\nMatchpoint’s Advanced Covalent Exploration (ACE) platform brings together a suite of proprietary tools to revolutionize the discovery and development of covalent medicines:\n<\/p>\n